They also investigated the effects of oral phycocyanobilin treatment (1 mg/kg) in an EAE-induced MS rat model, which showed a tendency to reduce clinical signs as well as significantly lower the levels of pro-inflammatory cytokines (IL-17, IFN-γ, and IL-6) [115]. The gene discussed is IL17A; the disease is myeloid sarcoma.